iSAM Funds UK Ltd Makes New $2.02 Million Investment in Gilead Sciences, Inc. $GILD

iSAM Funds UK Ltd bought a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) in the second quarter, HoldingsChannel reports. The firm bought 16,000 shares of the biopharmaceutical company’s stock, valued at approximately $2,021,000. Gilead Sciences makes up approximately 1.4% of iSAM Funds UK Ltd’s investment portfolio, making the stock its 7th largest holding.

Several other hedge funds have also modified their holdings of GILD. Brighton Jones LLC grew its holdings in Gilead Sciences by 20.6% during the fourth quarter. Brighton Jones LLC now owns 14,359 shares of the biopharmaceutical company’s stock worth $1,326,000 after acquiring an additional 2,450 shares during the period. Bison Wealth LLC acquired a new stake in Gilead Sciences in the fourth quarter valued at $215,000. Sivia Capital Partners LLC boosted its position in shares of Gilead Sciences by 16.8% during the 2nd quarter. Sivia Capital Partners LLC now owns 4,182 shares of the biopharmaceutical company’s stock worth $464,000 after purchasing an additional 602 shares in the last quarter. Ieq Capital LLC grew its stake in shares of Gilead Sciences by 12.0% during the 2nd quarter. Ieq Capital LLC now owns 118,695 shares of the biopharmaceutical company’s stock worth $13,160,000 after purchasing an additional 12,705 shares during the period. Finally, Diversify Advisory Services LLC grew its stake in shares of Gilead Sciences by 18.6% during the 2nd quarter. Diversify Advisory Services LLC now owns 4,296 shares of the biopharmaceutical company’s stock worth $516,000 after purchasing an additional 674 shares during the period. 83.67% of the stock is owned by institutional investors and hedge funds.

Key Gilead Sciences News

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Zacks upgraded Gilead to “Strong Buy.” The upgrade reflects improving expectations for the company’s earnings outlook and could encourage additional buying interest. Gilead Upgraded to Strong Buy
• Positive Sentiment: Zacks raised its 2027 EPS forecasts across every quarter and for the full year. Estimates increased to $2.09 for Q1, $2.24 for Q2, $2.43 for Q3, $2.60 for Q4 and $9.36 for full-year 2027, signaling modestly stronger anticipated profitability. Zacks Gilead Upgrade and Forecasts
• Positive Sentiment: FDA approval of Bixlenvo expands Gilead’s HIV portfolio. The single-tablet treatment is aimed at underserved patients and could provide a new source of growth, though commercial adoption will determine its financial impact. Bixlenvo HIV Growth Opportunity
• Neutral Sentiment: CEO Daniel O’Day sold 15,000 shares worth approximately $2.23 million. The transaction reduced his holdings by 2.53%, but it was executed under a pre-arranged Rule 10b5-1 plan, making it a weaker bearish signal than an unexpected discretionary sale. SEC Insider Trading Filing

Gilead Sciences Stock Performance

Shares of GILD opened at $149.61 on Thursday. Gilead Sciences, Inc. has a 12-month low of $108.46 and a 12-month high of $157.29. The stock has a market cap of $185.51 billion, a P/E ratio of -56.03 and a beta of 0.33. The company has a current ratio of 1.27, a quick ratio of 1.09 and a debt-to-equity ratio of 2.03. The company has a 50-day moving average of $135.66 and a two-hundred day moving average of $136.45.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Monday, August 3rd. The biopharmaceutical company reported ($6.75) EPS for the quarter, beating the consensus estimate of ($7.25) by $0.50. Gilead Sciences had a negative net margin of 10.64% and a negative return on equity of 2.11%. The business had revenue of $7.80 billion for the quarter, compared to analyst estimates of $7.40 billion. During the same period in the prior year, the business earned $2.01 earnings per share. The company’s quarterly revenue was up 10.6% on a year-over-year basis. As a group, research analysts predict that Gilead Sciences, Inc. will post -0.47 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 29th. Shareholders of record on Tuesday, September 15th will be issued a dividend of $0.82 per share. This represents a $3.28 dividend on an annualized basis and a yield of 2.2%. The ex-dividend date is Tuesday, September 15th. Gilead Sciences’s dividend payout ratio is -122.85%.

Wall Street Analysts Forecast Growth

Several analysts recently commented on GILD shares. Needham & Company LLC reiterated a “buy” rating and issued a $170.00 price objective on shares of Gilead Sciences in a research note on Wednesday, August 5th. Maxim Group upgraded shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $165.00 target price on the stock in a research report on Wednesday, May 20th. Zacks Research raised shares of Gilead Sciences from a “hold” rating to a “strong-buy” rating in a report on Monday. Daiwa Securities Group reduced their price target on shares of Gilead Sciences from $161.00 to $150.00 and set an “outperform” rating for the company in a research report on Tuesday, May 19th. Finally, Rothschild & Co Redburn decreased their price target on Gilead Sciences from $170.00 to $167.00 in a research note on Monday, May 11th. One analyst has rated the stock with a Strong Buy rating, twenty-four have given a Buy rating and five have given a Hold rating to the company’s stock. According to data from MarketBeat, Gilead Sciences presently has a consensus rating of “Moderate Buy” and an average price target of $158.04.

Insider Activity at Gilead Sciences

In other news, Director Anthony Welters sold 18,000 shares of the business’s stock in a transaction on Wednesday, August 26th. The stock was sold at an average price of $148.62, for a total value of $2,675,160.00. Following the completion of the transaction, the director directly owned 12,894 shares of the company’s stock, valued at $1,916,306.28. The trade was a 58.26% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel Patrick O’day sold 15,000 shares of the company’s stock in a transaction on Monday, August 3rd. The shares were sold at an average price of $130.31, for a total value of $1,954,650.00. Following the completion of the sale, the chief executive officer owned 592,133 shares in the company, valued at $77,160,851.23. This represents a 2.47% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 105,000 shares of company stock valued at $14,495,820 in the last ninety days. 0.30% of the stock is owned by insiders.

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.